Recently, the two new drug clinical trial (IND) applications submitted by Nuoyu Medicine to the FDA for the original theranostics integrated nuclear drug 68Ga/177Lu-NY108(NYM032) were successively approved. Norroy has obtained three clinical approvals in a few days, fully demonstrating the hard strength of research and development and the acceleration of innovation.
68Ga/177Lu-NY108(NYM032) is a small molecule compound with high affinity for prostate specific membrane antigen (PSMA). It is the same molecular precursor structure, and the indication is metastatic castration-resistant prostate cancer (mCRPC). The two can be combined for theranostics of prostate cancer. Preclinical and clinical results demonstrated the potential and advantages of 68Ga/177Lu-NY108(NYM032) for integrated prostate cancer treatment. 68Ga/177Lu-NY108(NYM032) is expected to become a new generation of integrated nuclear drug for prostate cancer theranostics, which brings more accurate, safer, more effective and more economical options for patients in the future.
At present, Norroy's original nuclear drug 177Lu-NY108(NYM032) for prostate cancer treatment and 68Ga-NY104(NYM005) for kidney cancer treatment have both received clinical approval in China and the United States, and China's original innovative nuclear drug has been shining on the world stage.
In order to further expand and deepen the global layout of the company's products, Norroy plans to submit IND applications every year in the future, and will continue to promote the key nodes of the projects, and strive to bring innovative nuclear drugs to the market as soon as possible, and bring more breakthrough options for global patients.
86-0510-88786189
